What can we expect for adolescents and adults with haemophilia switched to low-dose prophylaxis from episodic treatment for over 3 years? A real-world snapshot in China

Haemophilia. 2021 Sep;27(5):e624-e627. doi: 10.1111/hae.14361. Epub 2021 Jun 12.

Authors

Sha Liu¹, Ping-Yang Zhang², Zhi-Bin Jin¹, Yan-Hui Yuan³, Min Wu¹, Rong-Fu Zhou³

Affiliations

¹ Department of Ultrasound, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
² Department of Ultrasound Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
³ Department of Hematology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.

PMID: 34118092
DOI: 10.1111/hae.14361

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
China
Factor VIII / therapeutic use
Hemophilia A* / drug therapy
Hemophilia B* / drug therapy
Humans

Substances

Factor VIII